Stockscreener 앱 받기
1.23
0.82%
0.01
시장 영업 전:
1.25
0.02
+1.63%
전일 마감가:
$1.22
열려 있는:
$1.27
하루 거래량:
199.59K
Relative Volume:
0.28
시가총액:
$69.58M
수익:
$3.67M
순이익/손실:
$-13.83M
주가수익비율:
-4.3929
EPS:
-0.28
순현금흐름:
$-10.79M
1주 성능:
-0.81%
1개월 성능:
+9.82%
6개월 성능:
+64.79%
1년 성능:
-1.60%
1일 변동 폭
$1.2005
$1.27
1주일 범위
$1.16
$1.27
52주 변동 폭
$0.48
$1.57
Icecure Medical Ltd Stock (ICCM) Company Profile
ICCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.23 | 69.58M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Icecure Medical Ltd 주식(ICCM)의 최신 뉴스
Icecure Medical Announces Equity Distribution Agreement - TipRanks
IceCure Medical Reports Strong Growth and Anticipates FDA Approval in 2025 - TipRanks
IceCure Medical Reports 42% North American Growth as ProSense Cancer Treatment Shows 96% Success Rate - StockTitan
Investors bid IceCure Medical (NASDAQ:ICCM) up US$14m despite increasing losses YoY, taking five-year CAGR to 43% - Simply Wall St
The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing - Yahoo Finance
Financial Analysis: SANUWAVE Health (OTCMKTS:SNWV) versus IceCure Medical (NASDAQ:ICCM) - Defense World
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule - Kilgore News Herald
IceCure Medical regains full Nasdaq compliance - Medical Buyer
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minim - GuruFocus.com
IceCure to Meet Institutional Investors at the H.C. Wainwright a - GuruFocus.com
IceCure earns European patent win for next-gen cryoablation tech - Mass Device
IceCure Medical Ltd. Receives an Intention to Grant Notice from the European Patent Office - Marketscreener.com
Icecure Nicks Up On European OK For Connector - MENAFN.COM
IceCure Nicks Up on European OK for Connector - Baystreet.ca
European Patent Office Issues Intention to Grant Notice to IceCu - GuruFocus.com
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology - Marketscreener.com
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference - GuruFocus.com
IceCure Medical appoints new board director - Investing.com India
IceCure Medical appoints new board director By Investing.com - Investing.com Australia
Icecure Medical Appoints New Board Director with Financial Expertise - TipRanks
IceCure Medical Ltd Appoints Li Haixiang as Director - Marketscreener.com
IceCure Medical (NASDAQ:ICCM) Stock Price Down 0.4%Here's Why - MarketBeat
IceCure Medical (NASDAQ:ICCM) Shares Down 0.4% – What’s Next? - Defense World
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting - Marketscreener.com
IceCure Medical's ProSense Shows Breakthrough 5-Year Breast Cancer Treatment Results in Major Clinical Trial - StockTitan
Study Published in the British Journal of Radiology Demonstrates - GuruFocus.com
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - The Eastern Progress Online
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - The Eastern Progress Online
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - Kilgore News Herald
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery - The Eastern Progress Online
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - The Eastern Progress Online
Icecure Medical (XTAE:ICCM) 9-Day RSI : N/A (As of Dec. 05, 2024) - GuruFocus.com
ICCM (Icecure Medical) EBITDA : $-14.25 Mil (TTM As of Sep. 2024) - GuruFocus.com
IceCure's ProSense® Cryoablation Safe and Effective in Destructi - GuruFocus.com
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results - WV News
IceCure Medical Ltd (NASDAQ:ICCM) Q3 2024 Earnings Call Transcript - MSN
H.C. Wainwright reiterates Buy on IceCure Medical stock, FDA decision on ProSense expected soon - Investing.com
HC Wainwright Reiterates Buy Rating for IceCure Medical (NASDAQ:ICCM) - Defense World
IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
IceCure Medical’s sales grow 36% in nine months of 2024 - Medical Buyer
IceCure Receives Notice of Allowance from U.S. Patent and Tradem - GuruFocus.com
IceCure Medical Sees Strong Growth Amid ProSense® Adoption - TipRanks
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates - MSN
. By Investing.com - Investing.com
IceCure Medical Ltd Reports Earnings Results for the Nine Months Ended September 30, 2024 - Marketscreener.com
IceCure Medical Reports 36% Sales Growth in the First Nine | Trending From Our Network - Chicago Star Media
IceCure's Next-Generation Multiprobe Cryoablation Technology Iss - GuruFocus.com
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office - PR Newswire
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 - PR Newswire
IceCure gets favorable FDA AdCom vote for ProSense System - MSN
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Au - GuruFocus.com
Icecure Medical Ltd (ICCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.55%
자본화:
|
볼륨(24시간):